RMTI Stock Analysis: Buy, Sell, or Hold?
RMTI - Rockwell Medical, Inc. (DE) Common Stock
$5.54
0.35 (6.74%)
▲
5d:
+751.26%
30d:
+681.27%
90d:
+493.66%
WAIT
LOW Confidence
Analysis Updated: Jul 2, 2026 12:00 AM ET
Earnings: Aug 13, 2026
Get Alerted When RMTI Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR BETTER ENTRY: RMTI is 648.6% above its trading range ($0.74). Market expects 0% annual growth, but current price leaves little margin for error. While momentum could continue, risk/reward favors waiting for a pullback.
⏸️ WAIT FOR BETTER ENTRY: RMTI is 648.6% above its trading range ($0.74). Market expects 0% annual growth, but current price leaves little margin for error. While momentum could continue, risk/reward favors waiting for a pullback.
In-depth Analysis How we analyze
Valuation Analysis: RMTI is currently trading at $5.54, which is considered oversold relative to its 30-day fair value range of $0.63 to $0.74. From a valuation perspective, the stock is trading at a discount (Forward PE: -110.8) compared to its historical average (17.3). At these levels, the market is pricing in 0% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, RMTI is in a strong downtrend. The price is approaching resistance at $0.79. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 6.7% recently.
Market Sentiment: RMTI has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $30.00 (+441.5%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, RMTI is in a strong downtrend. The price is approaching resistance at $0.79. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 6.7% recently.
Market Sentiment: RMTI has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $30.00 (+441.5%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$0.63 -
$0.74
Company Quality Score
54/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
100.0%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+6.7%)
- BULLISH: Trading 441.5% below Wall St target ($30.00)
- BULLISH: Market expects only 0% annual growth - appears undervalued
- WARNING: Recommendation downgraded due to 648.6% overvaluation
Trading Range Analysis
30-Day Trading Range
$0.63 -
$0.74
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$0.64
Resistance Level
$0.79
Current Trend
Strong Downtrend
Technical data as of
Jun 9, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-110.80
Wall Street Target
$30.00
(+441.5%)
Revenue Growth (YoY)
-8.3%
Profit Margin
-8.0%
PE vs Historical
-110.8 vs 17.3
CHEAP
Share & Embed Analysis
Last updated: July 02, 2026 10:47 PM ET
Data refreshes hourly during market hours. Next update: 11:47 PM
Data refreshes hourly during market hours. Next update: 11:47 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is RMTI showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
25 analysts |
$194 | 62 BUY |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$105 | 63 BUY |
|
UTHR
United Therapeutics Corp… |
STRONG BUY
15 analysts |
$665 | 61 BUY |
|
ZTS
Zoetis Inc |
BUY
20 analysts |
$125 | 54 HOLD |
|
HCM
HUTCHMED DRC |
STRONG BUY
14 analysts |
$23 | 60 HOLD |
